Cell Therapeutics Presents Interim Results from Phase 2 Tosedostat Trial in Older Patients with AML or MDS at ASH

Cell Therapeutics (NASDAQ: CTIC ) today announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which